Drugs / GBS6
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04258995 | Feb → Sep 2020 | group B streptococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT03765073 | Jan 2019 → Mar 2024 | group B streptococcal infection | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05832502 Comparator | Oct 2022 → Sep 2025 | group B streptococcal infection | St George's, University of London | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-07-19 | Pfizer | Results Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate pfizer.com ↗
Results from an ongoing Phase 2 study in pregnant individuals showed the investigational vaccine, GBS6, was generally well-tolerated and generated robust maternal antibody responses that were efficiently transferred to infants |
| 2022-09-07 | Pfizer | Regulatory FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women pfizer.com ↗ |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GBS6 | “A hexavalent CPS-cross-reactive material 197 glycoconjugate vaccine (GBS6) is being developed as a maternal vaccine to prevent invasive group B streptococcus in young infants.” PMID 37467497 ↗ Jul 2023 |
| Modality | Vaccine | “hexavalent CPS-cross-reactive material 197 glycoconjugate vaccine” PMID 37467497 ↗ Jul 2023 |
| Route | Intramuscular | “GBS6 administered intramuscularly by injecting 0.5 mL into the deltoid muscle” NCT05832502 ↗ |